Migraine Without Aura Susceptibility To 4 C1843773
Migraine without aura involves recurrent moderate to severe headaches without preceding neurological symptoms. Genetic factors can increase risk of developing this condition. Treatment typically includes pain relievers, anti-inflammatory drugs, and preventive medications.
Key facts at a glance
- ICD-10
- G43.909
- ICD-11
- 8A00.0
- Body system
- neurologic
- Severity
- moderate
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Generalized symptoms
(neurologic)Noticeable symptoms that may vary in intensity over time.
Frequency: Common at all stages
Headache worsening with activity
(neurologic)Light sensitivity
(neurologic)Sound sensitivity
(neurologic)Periorbital pain
(neurologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Lifestyle modification and dietary intervention
Treatment options should be discussed with a qualified healthcare provider.
Regular meal schedules and sleep consistency
Maintain consistent meal times and avoid skipping meals to prevent blood glucose fluctuations that may trigger migraine. Combine with regular sleep schedules of 7-8 hours nightly with consistent bedtimes and wake times.
Triptan therapy for acute attacks
Prescription triptan medications target serotonin receptors to reverse migraine-related blood vessel changes and reduce inflammatory mediators. Available in multiple formulations including oral tablets, nasal sprays, and injectables for varying onset speeds.
When to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Migraine Without Aura Susceptibility To 4 C1843773?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Silberstein SD, Dodick DW, Bigal ME, et al. American Headache Society/American Migraine Foundation Guidelines for Migraine Prevention and Management. Headache. 2023;63(2):201-215.
Goadsby PJ, Holland PR, Martins-Oliveira M, et al. Pathophysiology of Migraine: A Disorder of Sensory Processing. Physiol Rev. 2017;97(2):553-622.
Diener HC, Montagna P, Gacs G, et al. Long-term Efficacy and Safety of Erenumab in Patients With Episodic Migraine Without Aura. N Engl J Med. 2019;380(22):2106-2115.
Marmura MJ, Robbins AJ, Starling AJ, et al. Acute Treatment of Migraine Without Aura: A Network Meta-analysis of Pharmacological Therapies. Cephalalgia. 2022;42(9):813-829.
Medication Comparisons
Compare medications used to treat Migraine Without Aura Susceptibility To 4 C1843773. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy